MPHHI, MultiSys launch Safify.comâa Covid-19 vaccination service platform
July 8, 2021 | 8:00 am
Safify, a digital health platform.
With the guidance and expertise of Metro Pacific Hospital Holdings Inc. (MPHHI) in the development of the platform, MultiSys seeks to provide an end-to-end digital tool that allows employers to digitally manage and administer their respective vaccination programs for the workplaceâfrom the supply chain, inventory, and vaccine administration.
MPHHI, the largest private hospital operator in the Philippines among whose hospitals include Makati Medical Center, Cardinal Santos Medical Center, Asian Hospital and Medical Center, Riverside Hospital in Bacolod, and Davao Doctors Hospital, is rolling out the platform to all eighteen (18) of its hospitals primarily in support of the MVP Groupâs vaccination program and other corporate clients.
Published July 8, 2021, 8:14 AM
Safify
Leading software solutions company Multisys Technologies Corporation debuts the newest addition to its 24 existing digital platforms, Safify, a social distancing and digital health platform.
With the guidance and expertise of Metro Pacific Hospital Holdings Inc. (MPHHI) in the development of the platform, MultiSys seeks to provide an end-to-end digital tool that allows employers to digitally manage and administer their respective vaccination program for the workplace from supply chain, inventory, and vaccine administration.
MPHHI, the largest private hospital operator in the Philippines among whose hospitals include Makati Medical Center, Cardinal Santos Medical Center, Asian Hospital and Medical Center, Riverside Hospital in Bacolod, and Davao Doctors Hospital, is rolling out the platform to all eighteen(18) of its hospitals primarily in support of the MVP Group’s vaccination program and other corporate clients.
Published June 4, 2021, 2:55 PM
(JANSEN ROMERO / MANILA BULLETIN FILE PHOTO)
Independent research group OCTA on Friday, June 4, expressed a “slight concern” due to the observed “uptick” of coronavirus disease (COVID-19) cases in some areas in Metro Manila.
OCTA Research fellow Dr. Guido David said the uptick in cases shows that the trend in Metro Manila remains “uneven.”
“Some LGUs [local government units] are decreasing, for example, San Juan has a 17 percent decrease in cases over the past week but we see LGUs like Parañaque and Caloocan which had a fairly significant increase in cases. We hope, of course, these are just fluctuations in the trend due to isolated events,” David said during a virtual forum organized by the Cardinal Santos Medical Center and OCTA Research on Friday.
She’s like a caring mother to all. This is how the late Second District Rep. Resurreccion Acop was described by her staff following her demise Friday morning (May 28).
Antipolo City Second District Rep. Resurreccion ‘Dr. Cion’ Marrero Acop In an interview with Manila Bulletin, three female staf
Published May 7, 2021, 3:15 PM
The recruitment of participants for clinical trial on the use of sleep-aid supplement melatonin as adjuvant treatment for coronavirus disease (COVID-19) in patients with pneumonia is ongoing, the Department of Science and Technology (DOST) has disclosed.
DOST Secretary Fortunato “Boy” T. de la Peña said the melatonin clinical trial is headed by Dr. Camilo C. Roa Jr. of the Manila Doctors Hospital and is implemented for nine months, from Sept. 7, 2020 to June 6, 2021.
(Manila Bulletin File Photo)
“Currently, recruitment of participants is ongoing,” he said.
He said the project has already started the recruitment in 12 out of the 17 hospital sites.